Bookmark
Forward
Successful Use of Glycoprotein IIb/IIIa Inhibitor Involving Severely Ill COVID-19 Patient.
Patrick Joseph Merrill, R Mark Bradburne
The Permanente journal 2021 Dec 14
Sizes of these terms reflect their relevance to your search.
This case report describes a successful outcome involving a patient with severe COVID-19 viral pneumonia utilizing a novel therapeutic approach with the glycoprotein IIb/IIIa inhibitor, eptifibatide.
Citation
Patrick Joseph Merrill, R Mark Bradburne.
Successful Use of Glycoprotein IIb/IIIa Inhibitor Involving Severely Ill COVID-19 Patient.
The Permanente journal.
2021 Dec 14;25
Mesh Tags
COVID-19
Eptifibatide
Humans
Peptides
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Substances
Peptides
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Eptifibatide
PMID: 35348110
View Full Text